Are you Dr. Chang?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 50 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
100 Stein Plz
Los Angeles, CA 90095Phone+1 310-473-8878
Summary
- Dr. Louis Chang, MD is a board certified ophthalmologist in Los Angeles, California. He is currently licensed to practice medicine in California and New York. He is affiliated with Good Samaritan Hospital.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical Center/UCLA Stein and Doheny Eye InstitutesResidency, Ophthalmology, 2004 - 2007
Los Angeles County-Harbor-UCLA Medical CenterInternship, Transitional Year, 2003 - 2004
Washington University in St. Louis School of MedicineClass of 2003
Certifications & Licensure
CA State Medical License 2013 - 2026
NY State Medical License 2007 - 2014- American Board of Ophthalmology Ophthalmology
Clinical Trials
- Intravitreal Gas for Vitreomacular Adhesion Start of enrollment: 2013 Nov 01
- Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration Start of enrollment: 2014 Sep 17
Publications & Presentations
PubMed
- 17 citationsHemi- and Central Retinal Vein Occlusion Associated with COVID-19 Infection in Young Patients without Known Risk Factors.Noy Ashkenazy, Nimesh A Patel, Jayanth Sridhar, Nicolas A Yannuzzi, Peter J Belin
Ophthalmology. Retina. 2022-06-01 - 12 citationsProphylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial.Clement K Chan, Maziar Lalezary, Prema Abraham, Michael Elman, Wesley Thomas Beaulieu
Ophthalmology. Retina. 2022-06-01 - 21 citationsHemi-retinal vein occlusion in a young patient with COVID-19Avni P. Finn, Rahul N. Khurana, Louis K. Chang
American Journal of Ophthalmology Case Reports. 2021-03-05
Press Mentions
Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal UseOctober 7th, 2020
